Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
December 8, 2025BloodOpen Access

An update: Safety and efficacy of GPRC5D targeting CAR-T cell therapy in relapsed/refractory multiple myeloma patients

View Full Paper
Ask AI
Bookmark
Share

Authors

ZYZhongtao YuanLLLin LiuYLYu Li

Discussion

Loading...

Member takes

Overview

Phase I trial shows 92.3% response rate in relapsed myeloma patients, indicating GPRC5D CAR-T may effectively treat refractory cases.

Key Points

  • Overall response rate for standard CAR-T was 92.3%, with 61.5% achieving complete response after treatment.
  • Standard GPRC5D CAR-T therapy showed manageable safety, with toxicities primarily hematological such as neutropenia and leukopenia.
  • Clinical trial involved 17 relapsed/refractory multiple myeloma patients over 296 days monitoring for outcomes.
  • Expanded findings suggest GPRC5D-targeted therapies may be effective for patients resistant to BCMA therapies.

Cite This Study

Yuan et al. (2025) studied this question.

synapsesocial.com/papers/69362f484fa91c937236d6dehttps://doi.org/10.1182/blood-2025-5854
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1BCMA-CART therapy in 29 cases of relapsed or refractory multiple myeloma:a retrospective study2025
  2. 2Long-term follow-up of patients with relapsed/refractory multiple myeloma after BCMA CAR-T-cell therapy2025 · 3 citations
  3. 3BCMA CAR T-cell therapy in newly diagnosed primary plasma cell leukemia ineligible for transplantation: An open label, single-arm, phase 2 study (CAREMM-002)2025 · 2 citations
  4. 4A dual targeting BCMA and CD19 fastcar-t (GC012F/AZD0120) as first-line therapy for newly diagnosed multiple myeloma2025 · 3 citations
  5. 5Preclinical development of an optimized manufacturing, CRISPR-edited, fully non-viral 1XX-enhanced anti-BCMA CAR-T therapy for multiple myeloma2025